Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA, 2 Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH USA, 3 Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH USA and 4 Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

[1]  J. Maciejewski,et al.  Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics , 2012 .

[2]  M. Craig,et al.  Azacitidine-associated Sweet's syndrome. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  B. Goh,et al.  A case of sweet’s syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma , 2012, Cutaneous and ocular toxicology.

[4]  B. Rini,et al.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. , 2012, Seminars in oncology.

[5]  M. McDevitt,et al.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes , 2011, Haematologica.

[6]  F. Trachtenberg,et al.  A pilot study of subcutaneous decitabine in β-thalassemia intermedia. , 2011, Blood.

[7]  V. Patel,et al.  Azacitidine: a new medication associated with Sweet syndrome. , 2011, Journal of the American Academy of Dermatology.

[8]  A. Verma,et al.  Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors , 2009, American journal of hematology.

[9]  S. Verstovsek,et al.  5-Azacitidine has limited therapeutic activity in myelofibrosis , 2009, Leukemia.

[10]  Scott E. Smith,et al.  Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis , 2008 .

[11]  H. Kantarjian,et al.  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis , 2008, Leukemia.

[12]  M. Tanioka,et al.  Splenic irradiation‐induced Sweet’s syndrome associated with preceding myelofibrosis , 2008, Clinical and experimental dermatology.

[13]  Philip R. Cohen.  Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis , 2007, Orphanet journal of rare diseases.

[14]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[15]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[16]  Philip R. Cohen,et al.  Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. , 1996, Journal of the American Academy of Dermatology.

[17]  R. Schwartz,et al.  Sweet's syndrome with myelofibrosis and leukemia: partial response to interferon. , 1995, Dermatology.

[18]  R. Sweet.  AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS. , 1964 .